Switch theme
Sign up to access all valuation multiples
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
2011
100
Last FY Revenue n/a
LTM EBITDA -$187M
-$11.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Annexon has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$187M.
In the most recent fiscal year, Annexon achieved revenue of n/a and an EBITDA of -$151M.
Annexon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Annexon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$187M | XXX | -$151M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$188M | XXX | -$154M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$173M | XXX | -$138M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Annexon's stock price is $2.
Annexon has current market cap of $224M, and EV of -$11.6M.
See Annexon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$11.6M | $224M | XXX | XXX | XXX | XXX | $-1.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Annexon has market cap of $224M and EV of -$11.6M.
Annexon's trades at n/a EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Annexon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Annexon has a P/E ratio of -1.3x.
See valuation multiples for Annexon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV (current) | -$11.6M | XXX | -$11.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 28.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnnexon's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Annexon's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Annexon's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Annexon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Annexon acquired XXX companies to date.
Last acquisition by Annexon was XXXXXXXX, XXXXX XXXXX XXXXXX . Annexon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Annexon founded? | Annexon was founded in 2011. |
| Where is Annexon headquartered? | Annexon is headquartered in United States of America. |
| How many employees does Annexon have? | As of today, Annexon has 100 employees. |
| Who is the CEO of Annexon? | Annexon's CEO is Mr. Douglas Love, Esq.. |
| Is Annexon publicy listed? | Yes, Annexon is a public company listed on NAS. |
| What is the stock symbol of Annexon? | Annexon trades under ANNX ticker. |
| When did Annexon go public? | Annexon went public in 2020. |
| Who are competitors of Annexon? | Similar companies to Annexon include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Annexon? | Annexon's current market cap is $224M |
| Is Annexon profitable? | Yes, Annexon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Annexon? | Annexon's last 12 months EBITDA is -$187M. |
| What is the current EV/EBITDA multiple of Annexon? | Current EBITDA multiple of Annexon is 0.1x. |
| What is the current FCF of Annexon? | Annexon's last 12 months FCF is -$89.9M. |
| What is the current EV/FCF multiple of Annexon? | Current FCF multiple of Annexon is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
